Wealthfront Advisers LLC Takes Position in 10x Genomics, Inc. (NASDAQ:TXG)

Wealthfront Advisers LLC acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 332,210 shares of the company's stock, valued at approximately $4,418,000. Wealthfront Advisers LLC owned 0.27% of 10x Genomics as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC lifted its holdings in shares of 10x Genomics by 1,108.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company's stock valued at $55,000 after buying an additional 2,240 shares during the period. First Horizon Advisors Inc. lifted its holdings in 10x Genomics by 53.3% in the third quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company's stock valued at $66,000 after acquiring an additional 1,012 shares during the period. Blue Trust Inc. boosted its position in 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after purchasing an additional 1,299 shares during the last quarter. KBC Group NV grew its stake in shares of 10x Genomics by 38.8% during the 3rd quarter. KBC Group NV now owns 3,225 shares of the company's stock valued at $73,000 after purchasing an additional 902 shares during the period. Finally, Sound Income Strategies LLC increased its position in shares of 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after purchasing an additional 1,330 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

10x Genomics Price Performance

10x Genomics stock opened at $9.88 on Friday. 10x Genomics, Inc. has a 1 year low of $9.27 and a 1 year high of $39.30. The firm's 50 day moving average price is $13.32 and its 200-day moving average price is $16.10. The stock has a market cap of $1.21 billion, a P/E ratio of -6.50 and a beta of 1.93.

Remove Ads

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Insider Transactions at 10x Genomics

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of 10x Genomics stock in a transaction that occurred on Friday, February 21st. The shares were bought at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the transaction, the director now owns 61,691 shares of the company's stock, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the sale, the insider now directly owns 335,324 shares in the company, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.03% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TXG. Citigroup dropped their price objective on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. UBS Group dropped their price target on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Canaccord Genuity Group reduced their price objective on 10x Genomics from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Barclays decreased their target price on 10x Genomics from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. Finally, Stifel Nicolaus cut their price target on 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $20.21.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.